JANX-007 is under clinical development by Janux Therapeutics and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase I drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how JANX-007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JANX-007 is under development for the treatment of metastatic castration resistant prostate cancer (mCRPC). The drug candidate is a bi-specific T cell engager (TCE) which acts by targeting cells expressing prostate specific membrane antigen (PSMA) and T cells. It is being developed based on Tumor Activated T Cell Engager (TRACTr) technology. It is administered through intravenous route.
Janux Therapeutics overview
Janux Therapeutics (Janux) is a clinical-stage biopharmaceutical company that develops novel immunotherapies to treat cancer. The company’s novel proprietary platforms T cell engager (TRACTr), and tumor activated immunomodulator (TRACIr) facilitate the manufacturing of monoclonal antibodies that delivers drug candidates. Janux products pipeline includes JANX007, JANX008, TROP2 and JANX009 that target prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2) and solid tumors (JANX009). The company product pipelines are used to treat colorectal cancer, head and neck cancer, non-small cell lung cancer, and other solid tumors. It works in collaboration with Merck Sharp and Dohme Corporation to develop TRACTr product candidates. Janux is headquartered in San Diego, California, the U.S.
For a complete picture of JANX-007’s drug-specific PTSR and LoA scores, buy the report here.